Prescient closes very productive September Quarter with strong cash position
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
This year, the ASX healthcare index gained a little more than 10% year to date....
Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a...
ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by...
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico...
In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.